Our findings indicate that, among patients with T2D receiving insulin therapy, the addition of GLP-1 RAs may confer substantial long-term benefits compared with DPP-4 inhibitors or sulfonylureas. This evidence concerns the gene INS and type 2 diabetes mellitus.